M.D., EVP, Head of R&D, CRISPR Therapeutics
Dr. Tony Ho is Head of R&D at CRISPR Therapeutics. Tony was previously SVP and Head of Oncology Integration and Innovation at AstraZeneca. He oversaw both development and commercialization of Lynparza and Imfinizi. Prior to joining AstraZeneca, Tony was the Neurology and Ophthalmology Clinical Section Head at Merck and led multiple development programs including the approval of Maxalt for pediatric migraine and Zioptan for glaucoma. Prior to joining Merck, Tony was the Co-Founder and CSO of Neuronyx, a regenerative medicine company. Tony received a B.S. from UCLA and a M.D. from the Johns Hopkins University. He was Assistant Neurology Professor at Hopkins. Tony described and elucidated the pathogenesis of acute motor axonal neuropathy (AMAN). He has published widely with over 80 papers and is co-inventor of 14 patents. Tony is currently adjunct Associate Professor of Neurology at University of Pennsylvania and Assistant Professor (Part-time) of Neurology at Johns Hopkins University.
Emerging Therapeutics Showcase: CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using CRISPR.
Brining Crispr To The Clinic
CRISPR Therapeutics is a leading gene editing company focused on developing transformative medicines in hemoglobinopathies, immuno-oncology, rare diseases and regenerative medicine using its CRISPR/Cas9 platform. The data supporting bringing CRISPR to the clinic for these programs will be discussed.